Anomalous endocrine feedback of peri-menopause in the etiology of type II ovarian cancer

Future Oncology

Volumn 9, Issue 9, 2013, Pages 1257-1261

  Bose, Chinmoy K ^a,b  

^a Netaji Subhas Chandra Bose Cancer Research Institute   (India)

^b UNIVERSITY OF BURDWAN   (India)

Author keywords

endocrine feedback; fallopian tube; fimbrial epithelium; FSHR; nonlinearity; ovarian surface epithelium; type II ovarian cancer

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FOLLITROPIN; FOLLITROPIN RECEPTOR; GONADOTROPIN; K RAS PROTEIN; LUTEINIZING HORMONE RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

ANOVULATION; CANCER STAGING; CHEMOPROPHYLAXIS; CLIMACTERIUM; FOLLITROPIN BLOOD LEVEL; GRANULOSA CELL; HORMONE RELEASE; HUMAN; MALIGNANT TRANSFORMATION; MENOPAUSE; NOTE; OVARY CANCER; OVARY CARCINOMA; OVULATION; POSTMENOPAUSE; PRECANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX CANCER; UTERINE TUBE; WESTERN BLOTTING;

ENDOCRINE GLANDS; FEMALE; HUMANS; MENOPAUSE; OVARIAN NEOPLASMS; RECEPTORS, FSH; TUMOR MARKERS, BIOLOGICAL;

EID: 84883295768     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.147     Document Type: Note

References (22)

1. Auersperg N. Ovarian surface epithelium as a source of ovarian cancers: Unwarranted speculation or evidence-based hypothesis? Gynecol. Oncol. 130(1), 246-251 (2013
2. Kuhn E, Kurman RJ, Shih IM. Ovarian cancer is an imported disease: Fact or fiction? Curr. Obstet. Gynecol. Rep. 1(1), 1-9 (2012
3. Erickson BK, Conner MG, Landen CN Jr. The role of the fallopian tube in the origin of ovarian cancer. Am. J. Obstet. Gynecol. doi:10.1016/j.ajog.04.019 (2013) (Epub ahead of print
4. Wang J, Lin L, Parkash V, Schwartz PE, Lauchlan SC, Zheng W. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: A novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems. Int. J. Cancer 103(3), 328-334 (2003
5. Zheng W, Lu JJ, Luo F et al. Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol. Oncol. 76(1), 80-88 (2000
6. Li G, Liu B, Liu Y. A dynamical model of the pulsatile secretion of the hypothalamo-pituitary-thyroid axis. Biosystems 35(1), 83-92 (1995
7. Zhang XY, Chen J, Zheng YF et al. Follicle stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo. Cancer Res. 69(16), 6506-6514 (2009
8. Schiffenbauer YS, Abramovitch R, Meir G et al. Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proc. Natl Acad. Sci. USA 94(24), 13203-13208 (1997
9. Wang J, Luo F, Lu JJ, Chen PK, Liu P, Zheng W. VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. Int. J. Cancer 97(2), 163-167 (2002
10. Saad AF, Hu W, Sood AK. Microenvironment and pathogenesis of epithelial ovarian cancer. Horm. Cancer 1(6), 277-290 (2010
11. Kindelberger DW, Lee Y, Miron A et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am. J. Surg. Pathol. 31, 161-169 (2007
12. Zhang XY, Ding JX, Tao X, Hua KQ. FSH stimulates expression of the embryonic gene HMGA2 by downregulating let-7 in normal fimbrial epithelial cells of ovarian high-grade serous carcinomas. Exp. Ther. Med. 5(1), 350-354 (2012
13. Zheng W, Magid MS, Kramer EE, Chen YT. Follicle-stimulating hormone receptor is expressed in human ovarian surface epithelium and fallopian tube. Am. J. Pathol. 148, 47-53 (1996
14. Bose CK. Role of nerve growth factor and FSH receptor in epithelial ovarian cancer. Reprod. Biomed. Online 11(2), 194-197 (2005
15. Radu A, Pichon C, Camparo P et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N. Engl. J. Med. 363(17), 1621-1630 (2010
16. Pike MC, Pearce CL, Peters R, Cozen W, Wan P, Wu AH. Hormonal factors and the risk of invasive ovarian cancer: A population based case-control study. Fertil. Steril. 82(1), 186-195 (2004
17. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J. Natl Cancer Inst. 94(1), 32-38 (2002
18. de Villiers TJ, Gass ML, Haines CJ et al. Global Consensus Statement on Menopausal Hormone Therapy. Climacteric 16(2), 203-204 (2013
19. Bose CK, Menon U, Dawnay A, Jacobs IJ. Gonadotrophin levels in postmenopausal women with epithelial ovarian cancer. J. Obstet. Gynaecol. India 51, 147-149 (2001
20. Menon U, Riley SC, Thomas J et al. Serum inhibin, activin, follistatin in postmenopausal women with epithelial ovarian cancer. Br. J. Obstet. Gynaecol. 107, 1069-1074 (1999
21. Bose CK. Nonlinear dynamics of endocrine feedback in hypothalamico- pituitary-ovarian (HPO) axis and its prospective role in screening and understanding etiology of ovarian cancer. J. Turkish-German Gynaecol. Assoc. 8(1), 346-349 (2007
22. Lenhard M, Lennerova T, Ditsch N et al. Opposed roles of follicle-stimulating hormone and luteinizing hormone receptors in ovarian cancer survival. Histopathology 58(6), 990-994 (2011